blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3820883

EP3820883 - PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  17.05.2024
Database last updated on 19.10.2024
FormerRequest for examination was made
Status updated on  16.04.2021
FormerThe international publication has been made
Status updated on  18.01.2020
Most recent event   Tooltip23.09.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark, California 94560 / US
[2021/20]
Inventor(s)01 / BHANDARI, Ashok
2808 Elsnab Court
Pleasanton, California 94588 / US
02 / FREDERICK, Brian Troy
8470 Glen Arbor Road
Ben Lomand, California 95005 / US
03 / SULLIVAN, David Clifford
4645 Hedgewick Avenue
Fremont, California 94538 / US
 [2021/20]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2021/20]Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
Application number, filing date19834098.612.07.2019
[2021/20]
WO2019US41665
Priority number, dateUS201862697218P12.07.2018         Original published format: US 201862697218 P
US201962872477P10.07.2019         Original published format: US 201962872477 P
[2021/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020014646
Date:16.01.2020
Language:EN
[2020/03]
Type: A1 Application with search report 
No.:EP3820883
Date:19.05.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 16.01.2020 takes the place of the publication of the European patent application.
[2021/20]
Search report(s)International search report - published on:US16.01.2020
(Supplementary) European search report - dispatched on:EP18.03.2022
ClassificationIPC:C07K7/08, C07K14/54, C07K7/02, A61K38/20
[2021/20]
CPC:
C07K7/08 (EP); C07K7/56 (US); C07K7/02 (EP);
A61K38/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/20]
TitleGerman:PEPTIDINHIBITOREN DES INTERLEUKIN-23-REZEPTORS UND DEREN VERWENDUNG ZUR BEHANDLUNG ENTZÜNDLICHER ERKRANKUNGEN[2021/20]
English:PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES[2021/20]
French:INHIBITEURS PEPTIDIQUES DU RÉCEPTEUR DE L'INTERLEUKINE-23 ET LEUR UTILISATION POUR TRAITER DES MALADIES INFLAMMATOIRES[2021/20]
Entry into regional phase12.02.2021National basic fee paid 
12.02.2021Search fee paid 
12.02.2021Designation fee(s) paid 
12.02.2021Examination fee paid 
Examination procedure12.02.2021Examination requested  [2021/20]
14.10.2022Amendment by applicant (claims and/or description)
21.05.2024Despatch of a communication from the examining division (Time limit: M04)
20.09.2024Reply to a communication from the examining division
Fees paidRenewal fee
15.07.2021Renewal fee patent year 03
27.07.2022Renewal fee patent year 04
14.06.2023Renewal fee patent year 05
12.06.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2017011820  (PROTAGONIST THERAPEUTICS INC [US], et al) [I] 1-14 * claim 7 *;
 [I]US9624268  (BOURNE GREGORY THOMAS [AU], et al) [I] 1-14 * SEQ ID 686, 980, 993 *;
 [I]WO2018089693  (PROTAGONIST THERAPEUTICS INC [US]) [I] 1-14* par.92,117-119, examples, claim 25 *
International search[Y]US5494897  (ISHIKAWA KIYOFUMI [JP], et al) [Y] 1-2, 12/2 * ; abstract; column 11, lines 1-21 *;
 [A]WO2016011208  (PROTAGONIST THERAPEUTICS INC [US], et al) [A] 1-2, 12/2 * ; whole document *;
 [Y]WO2017011820  (PROTAGONIST THERAPEUTICS INC [US], et al) [Y] 1-2, 12/2 * ; paragraphs [0010], [0012], [00148], [00206], [00305] *;
 [A]WO2018089693  (PROTAGONIST THERAPEUTICS INC [US]) [A] 1-2, 12/2* ; whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.